The scanner targets mid-volume labs, while the new software automates slide quality control processes.
Leica Biosystems unveiled three new digital pathology products at the Digital Pathology and AI Congress in London, expanding its clinical portfolio with the Aperio GT 180 DX scanner, Aperio CS5 DX scanner, and Aperio iQC DX software.
The Aperio GT 180 DX scanner builds on the company’s existing GT 450 DX platform, delivering image quality and speed designed for mid-volume laboratories. The new CS5 DX scanner provides scanning capabilities for 1×3 inch and 2×3 inch slides, with options for DICOM or SVS image format output.
The Aperio iQC DX software represents the company’s entry into automated quality control for digital pathology. The software standardizes QC processes to reduce variability and ensure consistency across laboratory operations. It automates artifact detection and reduces manual check requirements, allowing laboratory staff to maintain clinical standards while working more efficiently.
“The launch of the Aperio GT 180 DX scanner, Aperio CS5 DX scanner, and Aperio iQC DX software underscores our commitment to rapidly deliver effective clinical solutions providing a broad Aperio digital pathology portfolio to support the varied needs of pathology departments,” says Naveen Chandra, vice president and general manager of digital pathology at Leica Biosystems, in a release.
Regulatory Status and Availability
The Aperio HALO AP, Aperio GT 450 DX, Aperio GT 180 DX, Aperio CS5 DX, and Aperio iQC DX products carry CE marking under the In Vitro Diagnostic Regulation for diagnostic use. Other products in the company’s portfolio remain for research use only, and availability varies by country.
The company’s HALO AP and HALO Link software solutions are developed in partnership with Indica Labs and are exclusively available through Leica Biosystems.
“Delivering innovative solutions at a pace to support the needs of pathology diagnostics is at the core of our mission. Our drive is fueled by the urgent clinical need for faster, accurate diagnostics, and we remain focused on delivering transformational solutions that empower pathologists and improve patient outcomes,” says Chandra in a release.
ID 60897929 © Supphachai Salaeman | Dreamstime.com
